<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36709">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765621</url>
  </required_header>
  <id_info>
    <org_study_id>LHS022013</org_study_id>
    <nct_id>NCT01765621</nct_id>
  </id_info>
  <brief_title>Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions</brief_title>
  <acronym>DDI+</acronym>
  <official_title>Clinical and Economic Impact of a Web Based, Electronic Medical Record Interfaced Electronic Decision Support System Incorporating Pharmacogenetic Evaluation for Physicians Intended, Mainly for Drug-drug Interaction. A Controlled Study in an Ambulatory Health Maintenance Organization Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leumit Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leumit Health Services</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leumit Health Services, an health maintenance organization  operating in Israel, will
      incorporate a web-based, decision support system for handling drug-drug interactions and
      drug information, termed DDI+ reinforced with patient specific pharmacogenetic data. The
      investigators hypothesize that implementing such a system will reduce health-care
      expenditures (e.g., hospital admissions, referrals to ERs, Imaging procedures).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Hospital Admissions</measure>
    <time_frame>up to 12 month post initiation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Healthcare</condition>
  <arm_group>
    <arm_group_label>DDI+ and Pharmacogenetic data</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DDI+ System and Pharmacogenetic data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DDI+ System and Pharmacogenetic Data</intervention_name>
    <arm_group_label>DDI+ and Pharmacogenetic data</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Number of chronic concomitant drugs â‰¥5

          -  treated with 1 or more drugs with a well established interaction with 1 or more of
             the following CYP450 enzymes: 2c9, 2c19, 2d6

        Exclusion Criteria:

          -  Patients diagnosed with HIV/AIDS, and/or viral hepatitis B or C
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abraham Weizman, MD</last_name>
    <phone>+972-50-7277123</phone>
    <email>AWeizman@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leumit Health Services</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natan R Kahan, PhD</last_name>
      <phone>+972-50-5607187</phone>
      <email>nkahan@leumit.co.il</email>
    </contact>
    <investigator>
      <last_name>Abraham Weizman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mati Berkowitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>health care expenditure</keyword>
  <keyword>drug drug interactions</keyword>
  <keyword>electronic decision support systems</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>Potential Reduction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
